These could indicate serious complications
In fact, studies have shown that most (but not all) people do gain the weight back when they stop the medication
Injection site reactions are one of the most common side effects of injectables for eczema
Messer, who calls Mounjaro a more effective Wegovy. Indeed, in the clinical trial, participants lost 20% or more of their weight at the beginning of the trial
When the two overlap, some people may notice stronger nausea, lower alcohol tolerance, worse hangovers, or less interest in drinking
Key Phase 3 trials include: TRIUMPH-1: Retatrutide for obesity without type 2 diabetes TRIUMPH-2: Retatrutide for type 2 diabetes TRIUMPH-3: Retatrutide for obesity with type 2 diabetes TRIUMPH-4: Retatrutide for metabolic dysfunction-associated steatohepatitis (MASH) Results from these trials are expected between 2025 and 2027